Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Rmc-4630
2. Rmc4630
3. 2172652-48-9
4. Shp2-in-7
5. Sar442720
6. Sar-442720
7. [6-(2-amino-3-chloropyridin-4-yl)sulfanyl-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl]methanol
8. Vociprotafib [inn]
9. Unii-c4ybf9170l
10. C4ybf9170l
11. Schembl19785097
12. Gtpl12067
13. Ptpn11 Inhibitor Rmc-4630
14. Rmc 4630 [who-dd]
15. Glxc-25735
16. Ex-a5486
17. Nsc839698
18. Nsc-839698
19. Hy-141523
20. Cs-0179559
21. Compound A-290 [wo2018013597a1]
22. (6-((2-amino-3-chloropyridin-4-yl)sulfanyl)-3-((3s,4s)-4-amino- 3-methyl-2-oxa-8-azaspiro(4.5)decan-8-yl)- 5-methylpyrazin-2-yl)methanol
23. 2-pyrazinemethanol, 6-((2-amino-3-chloro-4-pyridinyl)thio)-3-((3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro(4.5)dec-8-yl)-5-methyl-
| Molecular Weight | 451.0 g/mol |
|---|---|
| Molecular Formula | C20H27ClN6O2S |
| XLogP3 | 1.2 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 4 |
| Exact Mass | 450.1604730 g/mol |
| Monoisotopic Mass | 450.1604730 g/mol |
| Topological Polar Surface Area | 149 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 584 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
A Vociprotafib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Vociprotafib, including repackagers and relabelers. The FDA regulates Vociprotafib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Vociprotafib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Vociprotafib supplier is an individual or a company that provides Vociprotafib active pharmaceutical ingredient (API) or Vociprotafib finished formulations upon request. The Vociprotafib suppliers may include Vociprotafib API manufacturers, exporters, distributors and traders.
Vociprotafib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Vociprotafib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Vociprotafib GMP manufacturer or Vociprotafib GMP API supplier for your needs.
A Vociprotafib CoA (Certificate of Analysis) is a formal document that attests to Vociprotafib's compliance with Vociprotafib specifications and serves as a tool for batch-level quality control.
Vociprotafib CoA mostly includes findings from lab analyses of a specific batch. For each Vociprotafib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Vociprotafib may be tested according to a variety of international standards, such as European Pharmacopoeia (Vociprotafib EP), Vociprotafib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Vociprotafib USP).
LOOKING FOR A SUPPLIER?
